Replying to @J__Cub @superpower
This is awesome, congrats. It shows the appetite of people to get information on the grey market peptide space. Imagine how this will take off when there is solid evidence in humans that these things are predictably safe and effective. Keep pushing forward.
Well said @davidasinclair
This is the hyperbole that often comes with an emerging field.
The longevity industry exists to exploit humanity, not to save it." - Seamus O'Mahony writes @TheLancet
But the reality is that there are many great people with skin in the game trying to build the datasets that will bring medicines to prevent health declines during aging. It will take time, there will be failed hypotheses, and there is hype. And with the hype comes those that want to ride that wave in many guises.
For those who care about making progress-avoid the noise.
"The longevity industry exists to exploit humanity, not to save it." - Seamus O'Mahony writes @TheLancet
Or, as he puts it, "the longevity industry is a goldrush without gold."
Talk about throwing out the baby with the bathwater!
Of course, the field is drowning in hype and commercial interests pushing unproven interventions. But that doesn't detract from the fact that slowing human aging - even if slightly - would have enormous health and medical benefits.
Manipulating human aging may prove harder than many in the field currently promise. But aging is no doubt malleable, so let's not lose sight of the field's long-term transformative potential.
The challenge is to tell hype from science, not to dismiss the science because of the hype.
Andrew Brack retweeted
Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find.
We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery.
I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science.
Applications are open for about 14 days: anthropic.com/news/open-call…
Subscribe and learn more about how @ARPA_H and HHS are transforming patient care and public health one discovery at a time!
Learn more 👇
The Oct. 8 ARPA-H Vitals newsletter drops soon. This week, you’ll find:
📆 A round-up of key program deadlines
🍿 A new video on a pioneering startup from America’s heartland
🗞️ ARPA-H stories hitting newsstands
Subscribe now & never miss a milestone. 📨 engage.arpa-h.gov/vitals
Replying to @ARPA_H
Excited to be speaking and happy to meet folks to talk longevity
Replying to @EricTopol
It actually supports parabiosis work: the aged environment inhibits young cell function, a young environment enhances old cell function.
Replying to @MaxUnfried
I can’t speak for your experience. I’d argue there was plenty of competition. But maybe the wrong games for stupid prizes!
Andrew Brack retweeted
I’m excited (and definitely a little nervous!) to share that I have started as Principal Investigator and faculty member at the Marcus Institute for Aging Research, a @harvardmed affliate!
For the past few years, I’ve been obsessed with a pretty simple question: how do we understand and measure human aging well enough to actually do something about it?
That question will be at the heart of what we build next.
Our lab will focus on computational geroscience, bringing together AI/ML, multi-omics, and large-scale human data to understand the biology of aging and, ultimately, find ways to intervene on it.
A big part of that will be building better biomarkers that can reliably measure aging and tell us whether an intervention is actually working. But I’m equally excited about what comes next: using computational tools to identify causal drivers of aging, discover new therapeutic targets, and help find and prioritize new therapies that could extend healthy lifespan.
The bigger goal is to close the loop between measurement, discovery, and intervention, connecting computational work with experiments, human studies, and clinical trials.
There is a lot to build, and an even longer list of things I still need to learn about running a lab. But that is probably what I’m most excited about. Building a team, learning from people across geroscience, medicine, computation, and industry, and tackling some interesting questions together.
I’m incredibly grateful to everyone at Yale who helped me get to this point, and very excited for what comes next at Harvard !
PS I am definitely looking to hire some smart computational biologists and ML/AI folks so definitely reach out!
Replying to @MaxUnfried @EdwardAnderton7
@MaxUnfried understanding and reversing frailty is in my mind the closest and most practical (but not easy) approach to ‘reversing’ aging.
Replying to @mu_anand @MelodyFRO
Congrats @mu_anand. I'm so excited for your journey and what y'all develop.
I was trying to narrow your focus to something thing that might be practical. I’m obsessed by getting shit done rather than waxing lyrical.
So, if an intervention given in mid to late life extended life by a few years pushed time to death, that cuts it? That’s a longevity drug?
Practically speaking this will be almost impossible to prove out in terms of drug development, and will likely lead to many false negatives of potential therapeutics. A practical example, the lifespan can differ by ten years different states within the US. Thought experiment, what if you shifted lifespan of a single state by a few years, say from 80-95. Is that a longevity drug?
Andrew Brack retweeted
IMO what matters more than the triage percentage is ppl fighting for a proposal that one person tanked for a crap reason
NIH study section triage line rumors drugmonkey.wordpress.com/202… via @drugmonkeyblog







